Vaxess Technologies

Terrestrial (Vaxess Technologies) is a private, clinical-stage biotech company pioneering a temperature-stable microarray patch (MAP) platform for transdermal drug delivery. Its core innovation involves dissolvable microneedles made from advanced biomaterials, which are designed to deliver a wide range of biologics and vaccines without the pain, sharps, or refrigeration requirements of traditional injections. The company is initially targeting the high-growth GLP-1 market and other large therapeutic areas, with a mission to make advanced therapies radically more convenient and accessible. Backed by venture capital and strategic partnerships, Terrestrial is advancing its platform through preclinical and clinical development.

Dissolvable microarray patch (MAP) platform using silk-derived biomaterials and polymers for pain-free, temperature-stable transdermal delivery of vaccines and large-molecule therapeutics.

Terrestrial competes with other drug delivery companies developing microneedle patches (e.g., Vaxxas, Micron Biomedical), as well as pharmaceutical firms investing in alternative delivery routes (oral, inhaled). Its primary competition is the entrenched standard of care: subcutaneous and intramuscular injections, which have established safety, efficacy, and manufacturing profiles.